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AbstrACt
Introduction Moisture damage (MD) exposure at work has 
been shown to increase the risk of new onset asthma and 
exacerbation of asthma. However, most of the studies in this 
field have been questionnaire studies. A small proportion 
of MD-exposed workers are diagnosed with asthma. Many 
patients with MD exposure at work referred to secondary 
healthcare report intermittent hoarseness, loss of voice 
or difficulty to inhale, referring to functional or organic 
problems of the larynx. For accurate treatment, proper 
differential diagnostics is paramount. We present an ongoing 
observational study in which we describe the prevalence 
of respiratory, voice and other symptoms related to MD at 
work in patients referred to secondary healthcare. Case-
control setting will be used to evaluate the frequencies of the 
background factors, bronchial hyperreactivity and laryngeal 
findings.
Methods and analysis The study sample consists of 
patients with workplace MD exposure and associated 
respiratory tract and/or voice symptoms referred to 
Tampere University Hospital. The clinical tests conducted 
to the study patients included comprehensive lung function 
tests, laboratory and skin prick tests, imaging and clinical 
evaluation by specialists of respiratory medicine, oto-rhino-
laryngology and phoniatrics. The exposure assessment was 
performed by an occupational physician. The study patients 
filled out a questionnaire on previous illnesses and other 
background factors, which for comparison was also sent to 
1500 Finnish-speaking people in the same hospital district 
randomly selected by the Finnish Population Information 
System. To explore how common laryngeal disorders and 
voice symptoms are in general, a part of the tests will be 
conducted to 50 asymptomatic volunteers.
Ethics and dissemination The regional ethics committee 
of Tampere University Hospital approved the study. All 
study subjects gave their written informed consent, which 
is required also from the controls. The results will be 
communicated locally and internationally as conference 
papers and journal articles.
IntroduCtIon
Indoor air quality problems are considered 
important risk factors for health problems 
worldwide.1 Indoor air-associated symptoms 
may be interrelated with different indoor air 
factors such as insufficient ventilation,2 unfa-
vourable temperature conditions,3 dry indoor 
air,4 dustiness,5 moisture damage (MD),1 
volatile organic compounds (VOC),6 and 
man-made mineral/vitreous fibres (MMMF/
MMVF).7 Even if we do not know the cause 
of symptoms,1 MD exposure at work has 
been shown to increase the risk of new onset 
asthma and exacerbation of asthma.8 9 Other 
illnesses or respiratory symptoms that have 
been associated with MD exposure include 
cough, wheezing, dyspnoea, rhinitis and 
upper respiratory tract symptoms.9 10 
In Finland, located in subarctic area, MDs 
in residences and schools are common.11 
Workers in office buildings commonly 
report symptoms and complaints associated 
with indoor air.12 13 There is also a growing 
public concern over MDs in buildings and 
their possible permanent effects on dwellers’ 
or workers’ health in Finland, even if there 
is minor evidence of serious or permanent 
illnesses other than asthma caused by expo-
sure to MD.9 14
strengths and limitations of this study
 ► This kind of comprehensive clinical study associat-
ed with moisture damage exposure at work has not 
been conducted before.
 ► This study will increase the understanding of re-
spiratory tract and voice symptoms and associated 
clinical findings in subjects exposed to moisture 
damage.
 ► Information on moisture damage exposure at work 
is based on documents from the workplace.
 ► Limitation of a cross-sectional study like this is that 
it is not possible to obtain information on causal 
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There are few studies describing the clinical findings 
in patients having symptoms when exposed to MD at 
work.15 16 Previous studies in this field have mainly been 
epidemiological,9 and most is known about children’s risk 
of developing symptoms in homes or schools with MD.17 18 
In majority of the studies, the assessment of exposure to 
MD or presence of symptoms or illnesses has been based 
on questionnaires.19 20 Furthermore, only a small propor-
tion of MD-exposed workers are diagnosed with asthma.8 
According to our clinical experience, many patients with 
work-related MD exposure and referred to secondary 
healthcare report intermittent hoarseness, loss of voice 
or difficulty to inhale, which would refer to functional or 
organic problems of the larynx.21 In the case of laryngeal 
disorders, asthma medication is not useful or may even 
worsen the symptoms if the larynx is sensitive to irrita-
tion.22 Coexisting with asthma, laryngeal disorders may 
be the cause of insufficient response to asthma treatment.
Studies over the past decades have provided important 
information on idiopathic environmental intolerance 
(IEI), in which a person has symptoms from different 
organ systems when in contact with an environmental 
factor that does not cause symptoms to most people.23 24 
In odour or multiple chemical sensitivity (MCS), a person 
reacts with symptoms in association with low levels of 
airborne chemicals that most people tolerate without 
problems.25 26 It seems that some proportion of the 
patients who have indoor air-associated symptoms in fact 
have IEI/MCS, but the frequency of this condition among 
these patients is not known.27
As a conclusion, there is a need for a clinical study on 
patients exposed to MD at workplace focusing especially 
on differential diagnostics between asthma and laryngeal 
symptoms, evidence of exposure to MDs and other indoor 
air risk factors and chemical sensitivity.
Aims of the study
In patients referred to secondary healthcare because of 
respiratory tract and/or voice symptoms associated to MD 
exposure at work, the aims are to
1. Describe the prevalence of different characteristics, 
symptoms and clinical test findings.
2. Find out the frequency of laryngeal symptoms and 
their possible influence on asthma diagnostics.
3. Explore the number of patients who fulfil the criteria 
of chemical sensitivity according to Quick Environ-
mental Exposure and Sensitivity Inventory (QEESI)© 
question series.28
4. Find out if there are connections between abovemen-
tioned symptoms and clinical findings and if it would 
be possible to allocate the clinical tests according to 
patient’s symptoms in secondary healthcare.
MEthods And AnAlysIs
The study is conducted at Tampere University Hospital, 
which is a secondary level referral centre for a popula-
tion of 530 000 and a tertiary level referral centre for a 
population of about 1 million people. Patients referred 
to departments of Occupational Medicine or Phoniatrics 
or Allergy Centre because of symptoms associated with 
indoor complaints at their workplace were interviewed as 
possible study subjects between October 2015 and June 
2017. The study inclusion criteria were as follows: (1) age 
between 18 and 65 years, (2) upper and/or lower respi-
ratory tract and/or voice symptoms, (3) symptoms asso-
ciated to workplace and (4) at least a strong suspicion of 
MD at the workplace (box 1). The exclusion criteria were 
as follows: (1) severe illness (eg, cancer) and (2) preg-
nancy. The study design is presented in figure 1. After the 
study subjects had given their informed signed consent, 
the work-associated symptoms were collected by a struc-
tured interview. If the patient was not sure if the symptom 
box 1 the criteria on which moisture damage (Md) at 
workplace was suspected.13
1. Indoor air perceived as mouldy or stuffy or otherwise unpleasant.
2. Signs of MDs: visible mould, moisture spots, discolouration of sur-
face materials, disengaging or blistering of flooring materials, crum-
bling of wall plastering, water leakages through ceilings (buckets on 
the floors), loose water on surfaces.
3. Renovations because of MDs previously made in the building.
4. Information on MD findings from employer or occupational and 
health safety personnel.
Figure 1 The study design on symptoms associated to 
moisture damage at workplace.
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was more frequent at work, it was not considered to be 
work associated.
The conducted clinical tests are presented in table 1. 
According to Finnish asthma guideline,29 diagnosis of 
asthma must be confirmed with a demonstration of 
variable airway obstruction in lung function measure-
ments: (1) peak expiratory flow (PEF) monitoring, (2) 
spirometry with bronchodilation test or (3) test for bron-
chial hyperreactivity (table 2). To confirm or rule out 
the asthma diagnosis, the patients carried out a 2-week 
PEF monitoring, spirometry with bronchodilation test 
and methacholine challenge test. The PEF monitoring 
included PEF measurements with Pinnacle peak flow 
metre for 2 weeks in the morning and evening before 
and after inhaled bronchodilator (0.4 mg salbutamol). 
Spirometry was performed according to European Respi-
ratory Society/American Thoracic Society guidelines,30 
and methacholine challenge test using dosimeter with 
controlled tidal breathing according to Finnish guide-
lines.31 To investigate if possible asthma is associated with 
work, the patients performed PEF monitoring at and off 
work32 with Vitalograph PEF/FEV Diary device. Diffusing 
capacity of the lungs33 and exhaled nitric oxide (FENO)
34 
were determined. Specialists of respiratory medicine (JK 
and LL), oto-rhino-laryngology (JN) and phoniatrics (SV) 
examined the patients. For diagnosing laryngeal disor-
ders, videolaryngostroboscopy with either rigid or fibre-
optic scope was performed, voice samples were recorded 
and also inspirograms were recorded before and after 
methacholine tests. Biopsy of nasal mucosa and a blood 
sample were taken and preserved for later analyses.
Exposure to MD at work was assessed from the docu-
ments of the building and indoor air quality investiga-
tions made at the workplace, if available, according to 
Finnish guidelines.35 A confirmed MD is graded into 
different severity categories, if sufficient information is 
available. Also, MMMFs, VOCs or problems in ventilation 
conditions at workplace were assessed if these had been 
measured.
As a non-responder analysis, of the patients who were 
invited but who did not take part in the study, age, symp-
toms, the presence of asthma diagnosis and exposure will 
be evaluated based on patient records.
To explore how common laryngeal disorders are in 
general, methacholine challenge test, voice recording, 
clinical examination by the specialist of phoniatrics 
including videolaryngostroboscopy, FENO and skin prick 
tests will be conducted to 50 asymptomatic volunteers 
adjusted for age and gender. The gathering of the volun-
teers began in August 2018 and it is our estimation that 
all the volunteers will be examined by the end of 2019.
Questionnaire/survey
The study patients and the volunteers fill out a question-
naire including questions on
Previous diseases, medication and upper and lower res-
piratory symptoms.36
Sinusitis symptoms (Sino-Nasal Outcome Test-2237).
Voice symptoms (Voice Activity and Participation Pro-
file,38 Voice Handicap Index,39 Voice Disorder Ques-
tionnaire40).
Laryngeal symptoms (Newcastle laryngeal hypersensi-
tivity questionnaire41).
Reflux symptoms (Reflux Symptom Index42).
Depression and anxiety symptoms (General Health 
Questionnaire GHQ-1243; Generalised Anxiety Disor-
der 7-item scale44).
Psychosocial work load45 and stress symptoms.46
Chemical sensitivity (QEESI©).28
To find out if the study group would have different 
background characteristics from the overall popu-
lation, the same questionnaire was sent to 1500 Finn-
ish-speaking people in the same hospital district 
Table 1 The clinical tests conducted to the study patients
Lung function tests Two-week serial PEF monitoring, PEF 
monitoring at and off work, spirometry 
with bronchodilation test, methacholine 
challenge test, exhaled nitric oxide 
(FENO), diffusing capacity of the lungs
Laboratory tests Sedimentation rate, C-reactive 
protein, blood count, serum total IgE, 
serum allergen-specific IgE (different 
fungi and storage mites Acarus Siro, 
Lepidoglyphus Destructor, Tyrophagus 
putrescentiae)
Skin prick tests Birch, timothy, mugwort, horse, dog, 
cat, Dermatophagoides Pteronyssinus 
house dust mite, latex, aspergillus 
fumigatus, storage mites Acarus Siro, 
Lepidoglyphus Destructor, Tyrophagus 
putrescentiae
Imaging Chest x-ray, cone beam CT of the 
paranasal sinuses
PEF, peak expiratory flow. 
Table 2 The criteria based on which asthma is diagnosed 
in different clinical tests29
Clinical test Criteria for asthma
Two-week PEF 
monitoring
At least three times
 ► At least 15% and 60 L/min 
improvements of PEF after 
bronchodilator.
 ► Diurnal variation of PEF at least 
20% and 60 L/min.
Spirometry At least 200 mL and 12% 




Cumulative methacholine dose 
0.6 mg or under results in 20% 
drop in FEV1 (PD20FEV1 <600 µg)
FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; PEF, peak expiratory flow. 
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randomly selected by the Finnish Population Informa-
tion System. The proportions of women and men and 
different age groups in this comparison material are 
similar to the study population.
sample size and power calculation
We estimated that a sample of 100 patients is enough to 
clinical deduction of the different characteristics of this 
patient group.
Concerning the population-based comparison mate-
rial, our aim was to get 400 questionnaire answers (ratio 
1:4) to increase the statistical power. Taking recent rather 
low survey response rates into account, we sent the ques-
tionnaire to 1500 people.
To assess if findings suggesting laryngeal disorders are 
more frequent among those who have respiratory tract 
or voice symptoms associated to workplace MD, data on 
frequency of laryngeal findings of asymptomatic people 
are needed. When analysing the findings of methacho-
line challenge test of 30 patients, signs of laryngeal disor-
ders were found in 62.5%. We estimated that among 
<30% of asymptomatic people there are such findings 
in the methacholine challenge test. In power calculation 
based on findings in the methacholine challenge test, the 
number of asymptomatic people tested would be 50 with 
80% force and 90% CI.
data analyses
We will analyse descriptive statistics (mean, median or 
proportion depending on the variable type and distri-
bution) for variables such as gender distribution and 
age of the patients and their lines of business. We will 
also analyse the frequencies of different symptoms the 
patients complain and how these are related to objective 
findings in different organ systems or new diagnoses of, 
for example, asthma or laryngeal dysfunction. We will 
describe the proportions of patients with significant find-
ings in medical assessment at different specialities (ENT, 
pulmonary and phoniatrics). We will compare frequen-
cies and intensities of different symptoms and clinical 
findings between the patients and symptomless controls. 
We will also compare different background factors of 
the study patients, such as perceived psychosocial work 
load, with controls of the population who answered to 
the same questionnaire as the study patients. Dichoto-
mous variables between two groups (patients vs controls 
or among patients with or without a certain finding) 
will be compared using χ2 test and Fisher’s exact test, 
while continuous variables between two groups will be 
analysed by t-test or Mann-Whitney test depending on 
the distributions. Multiple logistic regression will be 
used to assess independent predictors of certain clinical 
findings among the patients. Based on the relationship 
between symptoms and different objective findings, we 
aim to find ‘clinical triggers’ (certain sets of symptoms) 
that should prompt clinicians to refer patients to certain 
specialities.
Patient and public involvement
Patients or public were not involved in the design of the 
study. The study patients have received the results of their 
own tests, explanations for them and necessary treatment.
EthICs And dIssEMInAtIon
The regional ethics committee of Tampere University 
Hospital has approved the study (R14095). All study 
subjects gave their written informed consent, which is 
required also from the volunteers. The study adheres 
to good clinical research guidelines and the Helsinki 
Declaration.47
The results will be communicated locally as well as 
internationally as conference papers and journal articles.
Author affiliations
1Department of Occupational Medicine, Finnish Institute of Occupational Health, 
Tampere, Finland
2Department of Occupational Medicine, Tampere University Hospital, Tampere, 
Finland
3Department of Phoniatrics, Tampere University Hospital, Tampere, Finland
4Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
5Allergy Centre, Tampere University Hospital, Tampere, Finland
6Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland
Contributors JU is the head of the study group and PN is the principal researcher. 
All the writers took part in developing the study protocol: JU and PN planning the 
exposure assessment; JK, LL and AT the lung function diagnostics measures; JN 
the diagnostics of upper airways and SV, LK and EK the laryngeal investigations. All 
authors contributed to and approved the manuscript.
Funding This work was supported by the Tampere Tuberculosis Foundation and 
the Competitive State Research Financing of the Expert Responsibility area of 
Tampere University Hospital (grant number 9T069). 
Competing interests The study group report grants from Tampere Tuberculosis 
Foundation, grants from Competitive State Research Financing of the Expert 
Responsibility area of Tampere University Hospital, during the conduct of the study. 
Patient consent for publication Not required.
Ethics approval The regional ethics committee of Tampere University Hospital has 
approved the study (R14095).
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. WHO. WHO Guidelines for indoor air quality: dampness and mould. 
Copenhagen: WHO Regional Office for Europe, 2009. http://www. 
euro. who. int/__ data/ assets/ pdf_ file/ 0017/ 43325/ E92645. pdf.
 2. Muscatiello N, McCarthy A, Kielb C, et al. Classroom conditions and 
CO2 concentrations and teacher health symptom reporting in 10 
New York State Schools. Indoor Air 2015;25:157–67.
 3. Skyberg K, Skulberg KR, Eduard W, et al. Symptoms prevalence 
among office employees and associations to building characteristics. 
Indoor Air 2003;13:246–52.
 4. Wolkoff P. Indoor air humidity, air quality, and health - An overview. 
Int J Hyg Environ Health 2018;221:376–90.
 5. Schneider T. Dust and fibers as a cause of indoor environment 
problems. Scand J Work Environ Heal Suppl 2008;4:10–17.
 6. Salonen H, Pasanen AL, Lappalainen S, et al. Volatile organic 
compounds and formaldehyde as explaining factors for sensory 
irritation in office environments. J Occup Environ Hyg 2009;6:239–47.
H
ospital of Tam




ber 27, 2019 at Tam




pen: first published as 10.1136/bmjopen-2018-026485 on 25 June 2019. Downloaded from 
5Nynäs P, et al. BMJ Open 2019;9:e026485. doi:10.1136/bmjopen-2018-026485
Open access
 7. Salonen HJ, Lappalainen SK, Riuttala HM, et al. Man-made vitreous 
fibers in office buildings in the Helsinki area. J Occup Environ Hyg 
2009;6:624–31.
 8. Karvala K, Toskala E, Luukkonen R, et al. Prolonged exposure to 
damp and moldy workplaces and new-onset asthma. Int Arch Occup 
Environ Health 2011;84:713–21.
 9. Mendell MJ, Mirer AG, Cheung K, et al. Respiratory and allergic 
health effects of dampness, mold, and dampness-related agents: 
a review of the epidemiologic evidence. Environ Health Perspect 
2011;119:748–56.
 10. Jaakkola JJ, Hwang BF, Jaakkola MS. Home dampness and molds 
as determinants of allergic rhinitis in childhood: a 6-year, population-
based cohort study. Am J Epidemiol 2010;172:451–9.
 11. Täubel M, Karvonen AM, Reponen T, et al. Application of the 
Environmental Relative Moldiness Index in Finland. Appl Environ 
Microbiol 2016;82:578–84.
 12. Reijula K, Sundman-Digert C, Reijula K. Assessment of indoor 
air problems at work with a questionnaire. Occup Environ Med 
2004;61:33–8.
 13. Ministry of Social Affairs and Health F. Moisture Damages in 
Workplaces. Memo of the Working Group on Moisture Damages (in 
Finnish). Helsinki, 2009.
 14. Hurraß J, Heinzow B, Aurbach U, et al. Medical diagnostics for 
indoor mold exposure. Int J Hyg Environ Health 2017;220:305–28.
 15. White SK, Cox-Ganser JM, Benaise LG, et al. Work-related peak 
flow and asthma symptoms in a damp building. Occup Med 
2013;63:287–90.
 16. Hellgren UM, Hyvärinen M, Holopainen R, et al. Perceived indoor air 
quality, air-related symptoms and ventilation in Finnish hospitals. Int 
J Occup Med Environ Health 2011;24:48–56.
 17. Karvonen AM, Hyvärinen A, Korppi M, et al. Moisture damage and 
asthma: a birth cohort study. Pediatrics 2015;135:e598–606.
 18. Borràs-Santos A, Jacobs JH, Täubel M, et al. Dampness and mould 
in schools and respiratory symptoms in children: the HITEA study. 
Occup Environ Med 2013;70:681–7.
 19. Kim JL, Henneberger PK, Lohman S, et al. Impact of occupational 
exposures on exacerbation of asthma: a population-based asthma 
cohort study. BMC Pulm Med 2016;16:148.
 20. Kurth L, Virji MA, Storey E, et al. Current asthma and asthma-like 
symptoms among workers at a Veterans Administration Medical 
Center. Int J Hyg Environ Health 2017;220:1325–32.
 21. Moscato G, Pala G, Cullinan P, et al. EAACI Position Paper on 
assessment of cough in the workplace. Allergy 2014;69:292–304.
 22. Idrees M, FitzGerald JM. Vocal cord dysfunction in bronchial asthma. 
A review article. J Asthma 2015;52:327–35.
 23. Genuis SJ. Chemical sensitivity: pathophysiology or 
pathopsychology? Clin Ther 2013;35:572–7.
 24. Rossi S, Pitidis A. Multiple Chemical Sensitivity: Review of the State 
of the Art in Epidemiology, Diagnosis, and Future Perspectives. J 
Occup Environ Med 2018;60:138–46.
 25. Dantoft TM, Andersson L, Nordin S, et al. Chemical intolerance. Curr 
Rheumatol Rev 2015;11:167–84.
 26. Andersson L, Claeson AS, Dantoft TM, et al. Chemosensory 
perception, symptoms and autonomic responses during chemical 
exposure in multiple chemical sensitivity. Int Arch Occup Environ 
Health 2016;89:79–88.
 27. Karvala K, Sainio M, Palmquist E, et al. Building-Related 
Environmental Intolerance and Associated Health in the General 
Population. Int J Environ Res Public Health 2018;15:2047.
 28. Miller CS, Prihoda TJ. The Environmental Exposure and Sensitivity 
Inventory (EESI): a standardized approach for measuring chemical 
intolerances for research and clinical applications. Toxicol Ind Health 
1999;15:370–85.
 29. Haahtela T, Lehtimäki L, Ahonen E, et al. [Update on current care 
guidelines: asthma]. Duodecim 2013;129:994–5.
 30. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of 
spirometry. Eur Respir J 2005;26:319–38.
 31. Nieminen MM, Lahdensuo A, Kellomaeki L, et al. Methacholine 
bronchial challenge using a dosimeter with controlled tidal breathing. 
Thorax 1988;43:896–900.
 32. Burge PS. Use of serial measurements of peak flow in the diagnosis 
of occupational asthma. Occup Med 1993;8:279–94.
 33. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-
breath determination of carbon monoxide uptake in the lung. Eur 
Respir J 2005;26:720–35.
 34. Horváth I, Barnes PJ, Loukides S, et al. A European Respiratory 
Society technical standard: exhaled biomarkers in lung disease. Eur 
Respir J 2017;49:1600965.
 35. Latvala J, Karvala K, Sainio M, et al. Guidelines for Workplace 
and Occupational Health Actions in Indoor Air Problems (Finnish). 
Työterveyslaitos 2017 http://www. julkari. fi/ handle/ 10024/ 132078 
(Accessed 20 Aug 2018).
 36. Kilpeläinen M, Terho EO, Helenius H, et al. Validation of a new 
questionnaire on asthma, allergic rhinitis, and conjunctivitis in young 
adults. Allergy 2001;56:377–84.
 37. Morley AD, Sharp HR. A review of sinonasal outcome scoring 
systems - which is best? Clin Otolaryngol 2006;31:103–9.
 38. Sukanen O, Sihvo M, Rorarius E, et al. Voice Activity and 
Participation Profile (VAPP) in assessing the effects of voice disorders 
on patients' quality of life: validity and reliability of the Finnish version 
of VAPP. Logoped Phoniatr Vocol 2007;32:3–8.
 39. Alaluusua SJM. Psycho-social handicap of voice disorder and its 
rehabilitation: a pilot study of Finnish version of Voice Handicap Index 
[In Finnish] [master thesis], 2003.
 40. Sala E, Laine A, Simberg S, et al. The prevalence of voice disorders 
among day care center teachers compared with nurses: a 
questionnaire and clinical study. J Voice 2001;15:413–23.
 41. Vertigan AE, Bone SL, Gibson PG. Development and validation 
of the Newcastle laryngeal hypersensitivity questionnaire. Cough 
2014;10:1.
 42. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the 
reflux symptom index (RSI). J Voice 2002;16:274–7.
 43. Mäkikangas A, Feldt T, Kinnunen U, et al. The factor structure and 
factorial invariance of the 12-item General Health Questionnaire 
(GHQ-12) across time: evidence from two community-based 
samples. Psychol Assess 2006;18:444–51.
 44. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for 
assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 
2006;166:1092.
 45. Lahtinen M, Sundman-Digert C, Reijula K. Psychosocial work 
environment and indoor air problems: a questionnaire as a means of 
problem diagnosis. Occup Environ Med 2004;61:143–9.
 46. Elo AL, Leppänen A, Jahkola A. Validity of a single-item measure of 
stress symptoms. Scand J Work Environ Health 2003;29:444–51.








ber 27, 2019 at Tam




pen: first published as 10.1136/bmjopen-2018-026485 on 25 June 2019. Downloaded from 
